Healthcare investment powerhouse OrbiMed $1.86B 5th Credit Fund is officially closed, the New York-based firm announced Monday, after raising nearly $2 billion in commitments to bankroll the next wave of biotech and life sciences innovation.
The OrbiMed Royalty and Credit Opportunities Fund V will target growth-oriented healthcare companies across biopharma, medical devices, diagnostics, and tech-enabled health services, providing non-dilutive credit and royalty financing rather than traditional equity.
A Lifeline for Biotech in Shaky Markets
Equity markets have turned turbulent for biotech and life sciences players in recent years, squeezing capital access. OrbiMed General Partner Matthew Rizzo said the new fund aims to counter that trend.
“Our flexible, non-dilutive capital solutions can help portfolio companies grow and thrive despite volatile market conditions,” Rizzo said. “The OrbiMed platform is uniquely positioned to fund healthcare innovation and growth globally.”
Backed by Global Institutions
The fund drew backing from a wide range of sources — medical institutions, university endowments, pension funds, sovereign wealth funds, and family offices. More than 90% of capital came from returning long-term investors, underscoring trust in OrbiMed’s track record.
With $17 billion in assets under management, OrbiMed operates across private equity, public equity, and royalty/credit vehicles. Its global footprint includes offices in London, San Francisco, Shanghai, Hong Kong, Mumbai, and Herzliya, Israel.
